The clinical application characteristics of Insulin Degludec intermediates preparation

Insulin is gradually updated, making the efficacy and safety continue to increase. At present, the commonly used insulin preparations include intermediate-acting insulin (NPH), insulin glargine, insulin detemir, and insulin degludec. When choosing different basal insulins clinically, the risk of hypoglycemia, hypoglycemic efficacy, cardiovascular safety, and applicability should be fully evaluated. The crowd and many other aspects. So what are the clinical application characteristics of Insulin Degludec intermediates preparation? Next, let us take a look.

Here is that the content:

l In terms of the risk of hypoglycemia

l In terms of cardiovascular safety

In terms of the risk of hypoglycemia

In terms of the risk of hypoglycemia, compared with intermediate-acting insulin, long-term use of insulin glargine has a lower risk of hypoglycemia in type 2 diabetic patients; the overall incidence of hypoglycemia and severe hypoglycemia using insulin detemir is equivalent to that of insulin glargine, and the use of Insulin Degludec intermediates can reduce the risk of overall hypoglycemia and nocturnal hypoglycemia. Patients with type 2 diabetes who are at risk of hypoglycemia and high cardiovascular risk have a lower risk of hypoglycemia when treated with Insulin Degludec intermediates. In terms of efficacy of different types of basal insulin, insulin detemir improves fasting hemoglobin and fasting blood glucose levels similar to insulin glargine and is significantly better than intermediate-acting insulin; for patients with type 2 diabetes, the use of Insulin Degludec intermediates improves fasting more significantly than insulin glargine Blood glucose: For patients with type 2 diabetes, when they switch from other basal insulin to Insulin Degludec intermediates, the patients' glycosylated hemoglobin and fasting blood glucose levels are further improved significantly.

In terms of cardiovascular safety

In terms of cardiovascular safety, compared with intermediate-acting insulin, the use of detemir insulin significantly reduces the risk of cardiovascular death. Different types of basic insulin are suitable for different populations. Intermediate-acting insulin is suitable for adult type 1 and types 2 diabetes, gestational diabetes, and diabetes in children and adolescents; insulin glargine is suitable for adult type 1 and type 2 diabetes and children and adolescents aged 6 years and older; insulin detemir is suitable for adult type 1, Type 2 diabetes and diabetes in children and adolescents 6 years and older, can be considered during pregnancy; Insulin Degludec intermediates are currently applicable to adults with type 2 diabetes in China.

Chengdu Pukang has a professional R&D team with first-class technology, rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production. Parking has sufficient resources to provide process development, optimization and scale-up production The R & D will cooperate with the production to solve the problems encountered in the pilot scale-up process. We are more professional, more efficient to provide customers with high-quality products. The above is about the clinical application characteristics of Insulin Degludec intermediates preparations Related content, if you are interested in biology stable solution Insulin Degludec intermediates, injection grade 99% Insulin Degludec intermediates for energy metabolism, lab long-acting solid Insulin Degludec intermediates, TCA cycle synthesis crystal Insulin Degludec intermediates, you can consult our website, our website is www.pu-kang.com.